|
Oct 9
|
Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
|
|
Sep 27
|
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year?
|
|
Aug 29
|
Adagene to Participate in Investor Conferences in September
|
|
Jul 28
|
Adagene First Half 2024 Earnings: US$0.39 loss per share (vs US$0.094 loss in 1H 2023)
|
|
Jul 25
|
Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update
|
|
Jan 16
|
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
|
|
Jan 10
|
Adagene Inc.'s (NASDAQ:ADAG) market cap surged US$34m last week, retail investors who have a lot riding on the company were rewarded
|
|
Nov 3
|
Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023
|
|
Aug 31
|
Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update
|
|
May 25
|
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
|